Table 2.
Mean scores (standard deviation (SD)) for the European Organization for Research and Treatment of Cancers (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and endometrial cancer questionnaire EN24 from baseline to 2 weeks, 3 months and 1 year after robotic surgery
| Baseline n = 64 | 2 weeks n = 57 | 3 months n = 60 | 1 year n = 56 | Change: baseline to 2 weeks | p valuea | Change: baseline to 3 months | p valuea | Change: baseline to 1 year | p valuea | |
|---|---|---|---|---|---|---|---|---|---|---|
| QLQ-C30 | ||||||||||
| Functional scales | ||||||||||
| Global health status/QoL | 69.8 (20.8) n = 64 | 62.7 (22.1) n = 57 | 68.5 (21.0) n = 60 | 69.2 (25.6) n = 56 | − 8.77 (22.24) n = 57 | 0.0048* | − 1.81 (22.40) n = 60 | 0.32 | − 3.13 (28.05) n = 56 | 0.60 |
| Physical functioning | 82.0 (19.8) n = 64 | 71.3 (17.2) n = 56 | 80.1 (19.9) n = 60 | 80.8 (21.4) n = 56 | − 12.4 (18.5) n = 56 | < 0.0001* | − 2.03 (10.85) n = 60 | 0.017* | − 2.59 (12.78) n = 56 | 0.21 |
| Role functioning | 78.6 (28.2) n = 64 | 52.4 (33.1) n = 56 | 79.1 (25.8) n = 59 | 82.1 (28.2) n = 56 | − 30.1 (31.8) n = 56 | < 0.0001* | − 1.69 (26.75) n = 59 | 0.73 | − 1.79 (24.76) n = 56 | 0.79 |
| Emotional functioning | 68.0 (26.1) n = 64 | 73.9 (20.7) n = 57 | 81.1 (20.3) n = 60 | 82.7 (20.5) n = 56 | 3.27 (21.09) n = 57 | 0.30 | 12.3 (20.6) n = 60 | < 0.0001* | 9.92 (21.99) n = 56 | 0.0001* |
| Cognitive functioning | 79.9 (24.0) n = 64 | 83.0 (22.2) n = 57 | 85.8 (16.8) n = 60 | 88.1 (15.5) n = 56 | 1.46 (22.33) n = 57 | 0.60 | 4.72 (17.38) n = 60 | 0.042* | 4.17 (19.91) n = 56 | 0.18 |
| Social functioning | 84.6 (24.7) n = 64 | 79.8 (26.1) n = 57 | 85.0 (20.5) n = 60 | 84.8 (24.3) n = 56 | − 6.43 (30.50) n = 57 | 0.10 | -1.67 (19.58) n = 60 | 0.62 | − 4.46 (27.43) n = 56 | 0.26 |
| Symptom scales | ||||||||||
| Fatigue | 30.3 (23.8) n = 64 | 41.0 (24.0) n = 57 | 32.5 (26.6) n = 60 | 29.0 (27.7) n = 56 | 12.7 (23.4) n = 57 | < 0.0001* | 3.80 (22.79) n = 60 | 0.28 | 2.89 (17.66) n = 56 | 0.29 |
| Nausea/vomiting | 4.17 (8.91) n = 64 | 7.31 (12.21) n = 57 | 5.00 (13.48) n = 60 | 5.06 (13.07) n = 56 | 3.22 (13.52) n = 57 | 0.11 | 1.67 (13.62) n = 60 | 0.48 | 1.49 (13.95) n = 56 | 0.46 |
| Pain | 17.7 (25.5) n = 64 | 33.0 (27.9) n = 57 | 20.0 (28.1) n = 60 | 22.3 (30.4) n = 56 | 17.3 (22.7) n = 57 | < 0.0001* | 4.17 (23.29) n = 60 | 0.10 | 8.93 (26.96) n = 56 | 0.018* |
| Dyspnea | 15.9 (21.5) n = 63 | 21.4 (23.3) n = 56 | 22.2 (22.7) n = 60 | 22.6 (25.5) n = 56 | 7.27 (24.59) n = 55 | 0.029* | 6.78 (22.98) n = 59 | 0.041* | 7.88 (23.97) n = 55 | 0.026* |
| Insomnia | 29.2 (33.3) n = 64 | 29.8 (31.3) n = 57 | 28.3 (25.9) n = 60 | 25.0 (29.3) n = 56 | 1.75 (34.17) n = 57 | 0.66 | 1.11 (28.10) n = 60 | 0.79 | − 1.19 (24.59) n = 56 | 0.72 |
| Appetite loss | 10.4 (23.7) n = 64 | 16.1 (23.8) n = 56 | 9.44 (22.21) n = 60 | 8.93 (22.47) n = 56 | 7.14 (31.60) n = 56 | 0.077 | 0.556 (23.363) n = 60 | 0.95 | 2.98 (25.64) n = 56 | 0.41 |
| Constipation | 12.5 (25.5) n = 64 | 22.8 (31.0) n = 57 | 20.0 (30.2) n = 60 | 17.9 (29.8) n = 56 | 10.5 (37.4) n = 57 | 0.037* | 7.22 (23.84) n = 60 | 0.026* | 5.36 (20.87) n = 56 | 0.093 |
| Diarrhea | 6.77 (17.99) n = 64 | 12.3 (25.7) n = 57 | 10.00 (20.63) n = 60 | 10.7 (25.5) n = 56 | 7.02 (24.99) n = 57 | 0.055 | 5.00 (19.24) n = 60 | 0.068 | 5.95 (23.87) n = 56 | 0.10 |
| Financial problems | 7.81 (22.80) n = 64 | 7.60 (17.84) n = 57 | 5.56 (15.24) n = 60 | 5.36 (15.28) n = 56 | 0.000 (23.570) n = 57 | 0.98 | 0.000 (20.355) n = 60 | 1.00 | − 0.00 (22.92) n = 56 | 1.00 |
| EN24 | ||||||||||
| Functional scales | ||||||||||
| Sexual interest | 11.3 (21.7) n = 62 | 14.3 (25.3) n = 56 | 19.0 (25.3) n = 56 | 5.45 (22.00) n = 55 | 0.11 | 10.5 (24.9) n = 54 | 0.0039* | |||
| Sexual activity | 9.14 (20.17) n = 62 | 12.5 (20.7) n = 56 | 16.7 (24.6) n = 56 | 4.85 (22.61) n = 55 | 0.17 | 9.26 (23.72) n = 54 | 0.0072* | |||
| Sexual enjoyment | 69.7 (27.7) n = 11 | 64.3 (27.6) n = 14 | 50.0 (29.6) n = 20 | 0.000 (27.217) n = 7 | 1.00 | − 12.5 (24.8) n = 8 | 0.38 | |||
| Symptom scales | ||||||||||
| Lymphedema | 10.2 (18.0) n = 64 | 8.48 (18.13) n = 57 | 16.7 (21.0) n = 60 | 17.0 (25.1) n = 56 | − 0.877 (14.578) n = 57 | 0.66 | 6.94 (16.61) n = 60 | 0.0018* | 8.33 (22.47) n = 56 | 0.0025* |
| Urological symptoms | 22.0 (21.4) n = 64 | 13.4 (13.6) n = 57 | 20.0 (22.0) n = 60 | 20.8 (23.9) n = 56 | − 6.97 (20.79) n = 57 | 0.024* | -1.53 (16.81) n = 60 | 0.50 | − 0.595 (20.106) n = 56 | 0.72 |
| Gastrointestinal symptoms | 18.4 (18.4) n = 64 | 29.6 (19.6) n = 57 | 19.1 (14.6) n = 60 | 19.8 (21.2) n = 56 | 13.0 (16.9) n = 57 | < 0.0001* | 1.58 (14.73) n = 60 | 0.19 | 3.27 (18.22) n = 56 | 0.28 |
| Poor body Image | 15.9 (27.3) n = 64 | 11.9 (19.3) n = 56 | 16.7 (27.3) n = 60 | 13.4 (25.1) n = 56 | − 0.298 (23.245) n = 56 | 0.72 | 2.50 (33.02) n = 60 | 0.54 | 0.893 (30.221) n = 56 | 0.80 |
| Sexual/vaginal problems | 16.2 (29.5) n = 11 | 25.4 (28.4) n = 14 | 20.6 (23.6) n = 21 | 3.17 (26.23) | 0.75 | 1.39 (35.85) n = 55 | 0.66 | |||
| Pain in back and pelvis | 30.6 (32.1) n = 62 | 23.2 (24.6) n = 56 | 27.0 (31.5) n = 58 | 32.1 (34.2) n = 56 | − 6.79 (29.23) n = 54 | 0.10 | − 4.09 (28.22) n = 57 | 0.29 | 4.24 (30.80) n = 55 | 0.35 |
| Tingling/numbness | 13.0 (24.2) n = 64 | 4.76 (13.38) n = 56 | 21.5 (31.4) n = 59 | 28.6 (33.9) n = 56 | − 4.76 (23.29) n = 56 | 0.19 | 10.7 (30.0) n = 59 | 0.0059* | 18.5 (33.6) n = 56 | < 0.0001* |
| Muscular pain | 31.3 (33.5) n = 64 | 19.3 (26.7) n = 57 | 29.4 (32.5) n = 60 | 32.7 (37.3) n = 56 | − 9.94 (29.52) n = 57 | 0.0096* | 0.000 (29.433) n = 60 | 0.98 | 6.55 (35.63) n = 56 | 0.18 |
| Hair loss | 12.2 (23.4) n = 63 | 2.34 (13.89) n = 57 | 35.0 (41.8) n = 60 | 18.5 (29.8) n = 56 | − 7.14 (16.47) n = 56 | 0.0032* | 23.7 (42.9) n = 59 | < 0.0001* | 8.93 (31.46) n = 56 | 0.028* |
| Taste change | 8.33 (22.22) n = 64 | 13.5 (23.5) n = 57 | 16.7 (29.8) n = 60 | 9.52 (24.38) n = 56 | 6.43 (25.54) n = 57 | 0.042* | 8.33 (27.87) n = 60 | 0.032* | 2.98 (21.35) n = 56 | 0.34 |
Raw scores converted to 0–100 scale. Values in mean (SD). Values in bold represent a clinically meaningful and statistically significant change
QoL quality of life
*Statistically significant at the 5% level
aFor comparison over time, the Wilcoxon signed rank test was used